美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.36

+0.10590.31%

盤後：34.35-0.0059-0.02%19:59 EDT

成交量：1.97萬

成交額：67.75萬

市值：9,550.94萬

市盈率：- -

高：34.62

開：34.39

低：34.20

收：34.25

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：0.95

換手率：0.71%

股息：0.26

股息率：0.75%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

石藥集團(01093)：戈舍瑞林緩釋注射液(SYH9102注射液)在中國獲臨床試驗批准

石藥集團(01093)：戈舍瑞林緩釋注射液(SYH 9102注射液)在中國獲臨床試驗批准

石藥集團：SYH9102注射液獲中國臨床試驗批准，每月給藥一次

百利天恒：宜澤康III期臨床試驗完成首例受試者入組

百利天恒：宜澤康III期臨床試驗完成首例受試者入組

安進（AMGN）聯合療法III期臨床達主要終點

【券商聚焦】中郵證券維持翰森製藥（03692）買入評級指創新藥成增長核心

安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率

2026國談第五日：商保創新藥目錄價格協商開始多家藥企攜核藥、CAR-T新藥等重磅藥物進場

2026國談第五日：商保創新藥目錄價格協商開始多家藥企攜核藥、CAR-T新藥等重磅藥物進場

市場風向標：安進股價遭受重創

市場消息：派拉蒙天空之舞採取措施防範延期產生的成本，華納兄弟探索併購交易即將完成。

Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費

Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段

Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利

Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權

安進股價或創二十餘年來最大單日跌幅

福泰製藥(VRTX)股票9月8日盤中下跌3.06%：投資者必看的核心信息

TradingKey中文

吉利德科學(GILD)股票9月8日盤中下跌3.26%：釋放什麼信號？

TradingKey中文

諾華公司一款降膽固醇藥物在臨床試驗中失敗，Royalty Pharma股價下跌

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/IBBQ/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.3559,"timestamp":1789588800000,"preClose":34.25,"halted":0,"volume":19691,"hourTrading":{"tag":"盘后","latestPrice":34.35,"preClose":34.3559,"latestTime":"19:59 EDT","volume":40,"amount":1379.2795,"timestamp":1789603165220,"change":-0.0059,"changeRate":-0.000172,"amplitude":0},"delay":0,"changeRate":0.003091970802919659,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"已收盤","change":0.1059,"latestTime":"09-16 16:00:00 EDT","open":34.39,"high":34.62,"low":34.1992,"amount":677542.144902,"amplitude":0.012286,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789632000000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":34.25,"sharesOutstanding":2520001,"nav":34.27126,"aum":95274137.07126,"dividendRate":0.007478,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":34.28,"preClose":34.25,"latestTime":"09:29 EDT","volume":69,"amount":2360.8497660000003,"timestamp":1789565397037,"change":0.03,"changeRate":0.000876,"amplitude":0.008175},"postHourTrading":{"tag":"盘后","latestPrice":34.35,"preClose":34.3559,"latestTime":"19:59 EDT","volume":40,"amount":1379.2795,"timestamp":1789603165220,"change":-0.0059,"changeRate":-0.000172,"amplitude":0},"volumeRatio":0.950696,"impliedVol":0.1125,"impliedVolPercentile":0.4741},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.950696,"shares":2780001,"dividePrice":0.2569,"high":34.62,"amplitude":0.012286,"preClose":34.25,"low":34.1992,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.3559,"eps":0,"divideRate":0.007478,"volume":19691,"delay":0,"ttmEps":0,"open":34.39,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":34.9277,"twentyDayClose":34.6197,"sixtyDayClose":30.4995},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666846135","title":"石藥集團(01093)：戈舍瑞林緩釋注射液(SYH9102注射液)在中國獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2666846135","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666846135?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:09","pubTimestamp":1788948562,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团开发的促性腺激素释放激素受体激动剂戈舍瑞林缓释注射液(该产品)已获中国国家药品监督管理局批准，可在中国开展临床试验。该产品为全球首款获批临床的即用型戈舍瑞林缓释注射液，可通过与垂体GnRH受体高亲和力结合并诱导受体降调节，抑制促性腺激素分泌，降低血清睾酮及雌二醇水平，实现药物去势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0008368742.USD","MDTX","IE00B5MMRT66.SGD","BMED","LU1951186391.HKD","LU1807302812.USD","LU0072913022.USD","IE00BZ08YS42.EUR","BK1515","LU0501845795.SGD","IBBQ","LU0315179316.USD","LU0140636845.USD","LU0880133367.SGD","IE00BZ08YR35.GBP","HK0000165453.HKD","KURE","LU1226287529.USD","BK1521","LU1960683339.HKD","LU1226288253.USD","LU1993786604.SGD","LU1008478684.HKD","01093","IE00B543WZ88.USD","LU0326950275.SGD","LU2039709279.SGD","IE0008369823.USD","PSYK","LU0067412154.USD","IE00BZ08YT58.USD","LU1152091754.HKD","SG9999004220.SGD","LU0314109678.HKD","LU1226287792.SGD","LU1328277881.USD","LU1226287875.USD","IBBJ","BK1191","IE00B031HY20.USD","LU1152091168.USD","LU1813983027.USD","LU1226288170.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584690","title":"石藥集團(01093)：戈舍瑞林緩釋注射液(SYH 9102注射液)在中國獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584690","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584690?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:08","pubTimestamp":1788948523,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 公布，该集团开发的促性腺激素释放激素受体激动剂戈舍瑞林缓释注射液已获中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。该产品为全球首款获批临床的即用型戈舍瑞林缓释注射液，可通过与垂体GnRH受体高亲和力结合并诱导受体降调节，抑制促性腺激素分泌，降低血清睾酮及雌二醇水平，实现药物去势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","HK0000165453.HKD","IE00B543WZ88.USD","LU0880133367.SGD","LU0067412154.USD","IE00BZ08YS42.EUR","LU2039709279.SGD","BK1191","LU1813983027.USD","LU0315179316.USD","BK1521","LU1152091754.HKD","IBBJ","IE00B031HY20.USD","01093","LU1226287529.USD","SG9999004220.SGD","LU1008478684.HKD","IE00BZ08YR35.GBP","BK1515","LU1226287875.USD","LU1993786604.SGD","LU0501845795.SGD","LU0072913022.USD","LU1226287792.SGD","LU0314109678.HKD","LU1328277881.USD","LU1951186391.HKD","LU1226288253.USD","IE00B5MMRT66.SGD","LU1152091168.USD","LU0326950275.SGD","IE0008369823.USD","LU0140636845.USD","IE00BZ08YT58.USD","LU1226288170.HKD","KURE","IBBQ","LU1807302812.USD","MDTX","PSYK","LU1960683339.HKD","IE0008368742.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666845175","title":"石藥集團：SYH9102注射液獲中國臨床試驗批准，每月給藥一次","url":"https://stock-news.laohu8.com/highlight/detail?id=2666845175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666845175?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:08","pubTimestamp":1788948485,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","MDTX","PSYK","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666898185","title":"百利天恒：宜澤康III期臨床試驗完成首例受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2666898185","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666898185?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 17:09","pubTimestamp":1788944974,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBQ","PSYK","MDTX","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666589136","title":"百利天恒：宜澤康III期臨床試驗完成首例受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2666589136","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666589136?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 17:09","pubTimestamp":1788944940,"startTime":"0","endTime":"0","summary":"每经AI快讯，9月9日，百利天恒公告称，公司自主研发的全球首创双抗ADC宜泽康用于不可切除EGFR突变非小细胞肺癌同步放化疗后维持治疗的III期临床试验已完成首例受试者入组。每日经济新闻 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260909/c679746443.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260909/c679746443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0239","MDTX","91194","PSYK","688506","IBBJ","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666712586","title":"安進（AMGN）聯合療法III期臨床達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666712586","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666712586?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 16:59","pubTimestamp":1788944360,"startTime":"0","endTime":"0","summary":"金吾财经 | 安进公布，双特异性T细胞衔接器Imdelltra联合阿斯利康PD-L1抑制剂英飞凡，在广泛期小细胞肺癌的后期临床试验中实现总生存期延长。这家加州生物制药企业披露III期DeLLphi-305研究中期数据，该试验达成广泛期小细胞肺癌患者总生存期主要终点。该项全球试验评估该组合作为一线维持治疗，受试者既往接受过包含英飞凡的治疗且病情未发生进展。研究同时达成无进展生存期、客观缓解率两项次要终点。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","IBB","PBE","LU1267930573.SGD","LU0109394709.USD","LU2236285917.USD","BK4566","LU2462157665.USD","BK4585","BIB","IBBQ","LU2237443978.SGD","LU2456880835.USD","AZN","BK4599","LU0868494617.USD","TBXU","AMGN","LU0889565916.HKD","SG9999001440.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU0708994859.HKD","LU2237443895.HKD","LU1829250122.USD","IE00BFTCPJ56.SGD","LU0128525929.USD","BK4568","LU2112291526.USD","LU0122379950.USD","LU1571399168.USD","AZNH","LU2237443622.USD","IE00B2B36J28.USD","LU2242646821.SGD","BK4139","LU0432979614.USD","BK4534","IE00B4R5TH58.HKD","BK4533","BBH","BK4581","LU2237443382.USD","LU1023059063.AUD","LU0289739699.SGD","LU2089984988.USD","PJP","LU2242652126.USD","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666458356","title":"【券商聚焦】中郵證券維持翰森製藥（03692）買入評級 指創新藥成增長核心","url":"https://stock-news.laohu8.com/highlight/detail?id=2666458356","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666458356?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 15:32","pubTimestamp":1788939161,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中邮证券发布研报指，翰森制药 发布2026年中报，2026H1实现收入83.04亿元，同比增长11.7%；归母净利润42.58亿元，同比增长35.8%，利润高增部分得益于约6.31亿元的投资收益等一次性项目。创新药已成为公司增长的绝对核心。创新药收入达70.92亿元，同比增长15.4%，占总收入比重由去年同期的82.7%提升至85.4%。其中抗肿瘤领域收入54.73亿元，占总收入65.9%；非肿瘤领域收入28.31亿元，占总收入34.1%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991138","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","LNGR","MEDX","06978","KCE","159992","161027","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666309213","title":"安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309213","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666309213?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 10:39","pubTimestamp":1788921579,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4534","BK4139","IE00B4R5TH58.HKD","PSYK","BK4599","LU1057294990.SGD","LU0058720904.USD","LU1023059063.AUD","LU0889565916.HKD","TBXU","AMGN","IE00B2B36J28.USD","LU2468319806.SGD","BK4585","PJP","SG9999001440.SGD","LU1983299246.USD","LU1571399168.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","MDTX","LU0868494617.USD","LU0320765992.SGD","BMED","PBE","BK4588","BIB","LU1061106388.HKD","IBBQ","IBBJ","BBH","LU0122379950.USD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4566","LU2242652126.USD","IBB","IE00BJJMRZ35.SGD","BK4533","BK4581","LU2242646821.SGD","LU2112291526.USD","LU2089984988.USD","LU0289739699.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666305240","title":"2026國談第五日：商保創新藥目錄價格協商開始 多家藥企攜核藥、CAR-T新藥等重磅藥物進場","url":"https://stock-news.laohu8.com/highlight/detail?id=2666305240","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666305240?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 09:06","pubTimestamp":1788915970,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["159992","06978","BK1161","MEDX","BK1574","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666303231","title":"2026國談第五日：商保創新藥目錄價格協商開始 多家藥企攜核藥、CAR-T新藥等重磅藥物進場","url":"https://stock-news.laohu8.com/highlight/detail?id=2666303231","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666303231?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 08:20","pubTimestamp":1788913212,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112638879","title":"市場風向標：安進股價遭受重創","url":"https://stock-news.laohu8.com/highlight/detail?id=1112638879","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112638879?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 05:35","pubTimestamp":1788903338,"startTime":"0","endTime":"0","summary":"“这对安进而言，堪称最糟糕的结局。”——巴克莱分析师艾米丽·菲尔德如此评价。此前，诺华制药公布了其心脏病药物令人失望的试验结果，这一披露不仅让诺华自身承压，更给安进旗下一款重磅药物蒙上了厚厚的阴影。","market":"hk","thumbnail":"https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IBB","IE00B2B36J28.USD","BK4139","LU2468319806.SGD","TBXU","IE00BJT1NW94.SGD","LU2242646821.SGD","BK4599","LU0320765992.SGD","LU2112291526.USD","LU0868494617.USD","IE0002141913.USD","BK4534","BK4566","LU1983299246.USD","IE00B4R5TH58.HKD","LU2089984988.USD","BK4533","LU0122379950.USD","BIB","BK4581","SG9999001440.SGD","PBE","LU1571399168.USD","BK4588","LU1061106388.HKD","LU0289739699.SGD","LU0058720904.USD","IBBQ","BK4585","LU0889565916.HKD","LU1023059063.AUD","PJP","IE00BJJMRZ35.SGD","BBH","IE00BFTCPJ56.SGD","AMGN","LU2242652126.USD","LU1057294990.SGD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666370679","title":"市場消息：派拉蒙天空之舞採取措施防範延期產生的成本，華納兄弟探索併購交易即將完成。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666370679","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666370679?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 05:12","pubTimestamp":1788901933,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MNA","UYG","AAUM","BK4108","PBPH","CANC","DFMC","IYH","FFSM","IBBQ","PRVT","XLFI","BK4561","PSP","WMG","TBXU","RSPH","IEFN","PEVC","ACTV","BK4571","BK4588","MMID","RFG","VXF","BK4585","GTPE","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136308873","title":"Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費","url":"https://stock-news.laohu8.com/highlight/detail?id=1136308873","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136308873?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897732,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前披露，其在海外市场具备资格获取最高达2.8亿美元的里程碑款项，外加相应特许权使用费收入。据悉，这家生物科技企业所预期的资金流入将源自美国以外地区。对Assembly Biosciences而言，这笔潜在收入不仅反映其管线资产的外部合作价值，也可能为其后续研发投入提供坚实支撑。市场人士认为，此类非美国市场的收益结构有助于分散地域风险，增强公司财务韧性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934455277.USD","LU0122379950.USD","LU0289739699.SGD","SG9999015952.SGD","IE00BZ1G4Q59.USD","LU2324357040.USD","LU0109394709.USD","LU2087621335.USD","LU2112291526.USD","LU1061106388.HKD","SG9999015986.USD","IBB","LU0320765992.SGD","LU2468319806.SGD","BK4578","ASMB","BK4139","LU1585245621.USD","LU1674673691.USD","LU1023059063.AUD","IE00B19Z3581.USD","BK4550","BBH","BK4568","LU0114720955.EUR","LU1778281490.HKD","IE0002270589.USD","LU1066051498.USD","SG9999015978.USD","BIB","LU0965508806.USD","LU2089984988.USD","MEDI","TMED","LU1674673428.USD","IE00BKVL7J92.USD","LU0889565916.HKD","LU1839511570.USD","LU0058720904.USD","LU1571399168.USD","LU1057294990.SGD","IE00B19Z3B42.SGD","TBXU","LU0965509010.AUD","LU1430594728.SGD","LU0234570918.USD","BK4585","LU1934455194.USD","LU1037948541.HKD","LU1037948897.HKD","LU1934455863.HKD","LU2357627491.SGD","SG9999015945.SGD","BK4532","LU1066053197.SGD","BK4583","IE00BSNM7G36.USD","GILD","LU0823416689.USD","LU0861579265.USD","BK4566","LU0965509101.SGD","LU0882574055.USD","BK4588","LU0965509283.SGD","IE00B3T34201.USD","IBBQ","IE00B7SZLL34.SGD","LU0859254822.USD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154623157","title":"Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1154623157","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154623157?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897731,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前宣布，其研发管线中的候选药物Gs-1179有望在2026年年底之前顺利迈入针对生殖器疱疹的二期临床试验阶段。生殖器疱疹作为一种常见的性传播感染疾病，全球患者群体庞大，对创新疗法的需求十分迫切。Assembly Biosciences正积极加速该药物的研发进程，以期尽早为患者带来新的治疗选择。业内分析人士指出，若Gs-1179能够顺利通过后续试验的严格考验，将可能重塑该适应症的市场格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","BK4139","LU0114720955.EUR","LU1057294990.SGD","LU1066051498.USD","LU0058720904.USD","LU1778281490.HKD","LU1674673691.USD","LU1037948541.HKD","LU1023059063.AUD","IE00BZ1G4Q59.USD","LU0889565916.HKD","IE00BKVL7J92.USD","LU1934455194.USD","LU1585245621.USD","BK4550","TBXU","LU2468319806.SGD","SG9999015978.USD","BK4585","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU1571399168.USD","LU0965509010.AUD","LU1430594728.SGD","LU1066053197.SGD","BK4583","LU0109394709.USD","LU2357627491.SGD","LU0965509101.SGD","LU0320765992.SGD","BMED","SG9999015952.SGD","LU1674673428.USD","IE00BSNM7G36.USD","BK4588","GILD","TMED","IE00B3T34201.USD","LU0965508806.USD","IE0002270589.USD","MEDI","BIB","LU1061106388.HKD","LU0234570918.USD","IBBQ","LU2087621335.USD","BBH","LU0122379950.USD","ASMB","BK4566","LU0861579265.USD","LU1037948897.HKD","LU1839511570.USD","LU1934455277.USD","LU1934455863.HKD","BK4568","IE00B7SZLL34.SGD","LU0823416689.USD","LU2324357040.USD","BK4578","IBB","SG9999015986.USD","LU0965509283.SGD","LU2112291526.USD","BK4532","LU2089984988.USD","SG9999015945.SGD","LU0859254822.USD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115029168","title":"Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利","url":"https://stock-news.laohu8.com/highlight/detail?id=1115029168","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115029168?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897702,"startTime":"0","endTime":"0","summary":"Assembly Biosciences宣布，吉利德科学已保留其HSV HPI项目的独家临床开发及商业化权利。这一决定标志着双方合作进一步深化，吉利德将全权主导该项目的后续推进与市场布局。对于Assembly Biosciences而言，此举不仅明确了合作伙伴的战略优先级，也为其自身聚焦其他管线资源提供了更大灵活性。业内观察人士指出，HSV HPI项目的独家授权，反映了吉利德在抗病毒治疗领域持续加码的雄心，同时也凸显了该类创新疗法在未被满足的医疗需求中所蕴含的巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","LU0109394709.USD","IBB","BK4139","LU0859254822.USD","LU2468319806.SGD","TBXU","IE00B19Z3B42.SGD","BK4532","LU0320765992.SGD","LU1839511570.USD","LU2112291526.USD","MEDI","IE0002270589.USD","BK4566","LU0114720955.EUR","IE00BSNM7G36.USD","LU0823416689.USD","LU1430594728.SGD","LU2089984988.USD","LU1934455194.USD","IE00BZ1G4Q59.USD","LU0965509010.AUD","LU1037948541.HKD","LU1585245621.USD","SG9999015945.SGD","LU0122379950.USD","LU1778281490.HKD","GILD","IE00B7SZLL34.SGD","BIB","LU2357627491.SGD","LU0965509101.SGD","LU0861579265.USD","LU0965508806.USD","SG9999015978.USD","LU2324357040.USD","LU1571399168.USD","LU1934455277.USD","LU1037948897.HKD","BK4588","SG9999015952.SGD","LU1061106388.HKD","LU1934455863.HKD","BK4583","LU2087621335.USD","BMED","BK4550","IBBQ","LU0058720904.USD","LU0234570918.USD","LU0965509283.SGD","BK4585","TMED","IE00BKVL7J92.USD","ASMB","LU0882574055.USD","LU0889565916.HKD","LU1023059063.AUD","IE00B19Z3581.USD","IE00B3T34201.USD","LU1066051498.USD","BK4568","LU1674673691.USD","SG9999015986.USD","BBH","LU1066053197.SGD","LU1057294990.SGD","LU0289739699.SGD","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179230759","title":"Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權","url":"https://stock-news.laohu8.com/highlight/detail?id=1179230759","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179230759?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897669,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司已正式行使与吉利德科学就HSV解旋酶-引物酶抑制剂项目达成的美国利润分成选择权。这一战略举措标志着双方合作进入新阶段，有望加速该抗病毒疗法的临床开发与商业化进程。通过行使该选择权，Assembly Biosciences将能够分享该药物在美国市场的未来收益，同时借助吉利德在抗病毒领域的深厚积累与市场渠道，共同推进这一潜在重磅药物的落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0289739699.SGD","SG9999015945.SGD","IE00B3T34201.USD","BIB","LU0109394709.USD","LU1057294990.SGD","LU1778281490.HKD","LU2324357040.USD","BK4588","LU1061106388.HKD","ASMB","LU0889565916.HKD","LU1674673691.USD","LU0320765992.SGD","LU1839511570.USD","BK4139","LU0234570918.USD","BMED","LU0122379950.USD","LU2087621335.USD","LU0965509101.SGD","IE0002270589.USD","LU1066053197.SGD","BK4585","SG9999015978.USD","SG9999015986.USD","LU0859254822.USD","LU0861579265.USD","LU1430594728.SGD","IE00BZ1G4Q59.USD","LU0965509010.AUD","LU2468319806.SGD","LU0058720904.USD","LU0882574055.USD","LU1934455863.HKD","LU0114720955.EUR","IE00BSNM7G36.USD","MEDI","TMED","LU0965509283.SGD","LU1066051498.USD","LU1934455277.USD","BK4532","IE00B19Z3581.USD","BK4568","IBB","LU0965508806.USD","LU1585245621.USD","TBXU","LU1037948541.HKD","LU1674673428.USD","LU1037948897.HKD","IBBQ","BBH","BK4578","LU2089984988.USD","LU2112291526.USD","BK4550","GILD","BK4566","LU2357627491.SGD","SG9999015952.SGD","IE00B19Z3B42.SGD","LU1934455194.USD","LU1571399168.USD","IE00B7SZLL34.SGD","IE00BKVL7J92.USD","LU1023059063.AUD","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111756325","title":"安進股價或創二十餘年來最大單日跌幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1111756325","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111756325?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 02:23","pubTimestamp":1788891793,"startTime":"0","endTime":"0","summary":"安进公司股价近期重挫逾9%，这一跌幅令这家生物技术巨头有望迎来自2000年10月以来最惨淡的单日表现。此番暴跌的导火索，源于诺华制药宣布其心脏病药物pelacarsen在降低心血管事件风险方面未能优于安慰剂，试验宣告失败。周二，礼来股价小幅下挫1.9%。安进的跌势因BMO资本市场的下调评级而进一步加剧，使其沦为标普500指数和纳斯达克100指数中的最大输家。","market":"hk","thumbnail":"https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","LU0868494617.USD","LU1023059063.AUD","LU1057294990.SGD","LU2112291526.USD","IBBQ","LU0122379950.USD","LU1571399168.USD","LU0889565916.HKD","AMGN","PJP","BK4533","BK4599","IE0009355771.USD","SG9999001440.SGD","LU0289739699.SGD","LU2242652126.USD","BK4566","IBB","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4534","LU2089984988.USD","BIB","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","04332","BK4139","LU0109394709.USD","LU0320765992.SGD","BK4585","PBE","LU0058720904.USD","LU2468319806.SGD","LU1061106388.HKD","BK4588","IE00BJJMRZ35.SGD","IE0002141913.USD","LU1983299246.USD","BBH","LU2242646821.SGD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374214","title":"福泰製藥(VRTX)股票9月8日盤中下跌3.06%：投資者必看的核心信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374214","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374214?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 02:16","pubTimestamp":1788891392,"startTime":"0","endTime":"0","summary":"• Vertex 股价在反弹至接近52周高点后遭遇波动与获利回吐。\n• 对 Crinetics 的收购整合要到2029年才能实现非GAAP增盈。\n• 技术指标显示 MACD 呈中性，RSI 呈中性，威廉指标（Williams %R）呈超卖状态。","market":"sh","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156640-market-movers-vrtx-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU2417539215.USD","SG9999013999.USD","LU2362541513.USD","BK4588","IE0002270589.USD","IE00B19Z3581.USD","IE00B4R5TH58.HKD","LU1674673428.USD","LU1778281490.HKD","LU0234570918.USD","SG9999001176.USD","LU0079474960.USD","BK4585","LU0417517546.SGD","LU1035775433.USD","BK4532","IBB","LU1069344957.HKD","GNMX","PBE","LU0889565916.HKD","LU0432979614.USD","IDNA","BBH","IBBQ","SG9999001176.SGD","LU1674673691.USD","LU2362541273.HKD","LU1093756325.SGD","BIB","LU1430594728.SGD","BK4533","IE00BJT1NW94.SGD","LU0061475181.USD","IE00B2B36J28.USD","LU2362540622.SGD","SGXZ57979304.SGD","TBXU","LU0289739699.SGD","LU1585245621.USD","IE0002141913.USD","IE0009355771.USD","LU0256863811.USD","LU1093756168.USD","LU2237438978.USD","IE00B894F039.SGD","VRTX","BK4139","IE00B19Z9Z06.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374570","title":"吉利德科學(GILD)股票9月8日盤中下跌3.26%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374570","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374570?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 01:16","pubTimestamp":1788887780,"startTime":"0","endTime":"0","summary":"• 吉利德在经历了长达数月的持续上涨后，因获利回吐而出现回调。\n• 强劲的第二季度营收主要受其旗舰 HIV 和 Trodelvy 产品线的推动。\n• 分析师维持“买入”评级，平均目标价为 157.79 美元。","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156554-market-movers-gild-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","LU0965508806.USD","LU1674673691.USD","MEDI","LU1037948541.HKD","SG9999015986.USD","IE00B19Z3B42.SGD","IE0002270589.USD","LU1934455277.USD","BK4585","LU0114720955.EUR","LU2324357040.USD","IE00BZ1G4Q59.USD","TMED","LU0109394709.USD","GILD","IBBQ","LU1571399168.USD","BMED","TBXU","BK4583","SG9999015952.SGD","LU0058720904.USD","BK4568","BK4578","SG9999015978.USD","LU0289739699.SGD","LU0882574055.USD","IBB","LU0823416689.USD","BK4532","IE00B19Z3581.USD","LU1430594728.SGD","IE00B3T34201.USD","BIB","LU1839511570.USD","SG9999015945.SGD","LU2087621335.USD","LU2112291526.USD","LU0122379950.USD","LU0859254822.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","LU0320765992.SGD","LU0965509101.SGD","LU1023059063.AUD","IE00B7SZLL34.SGD","LU1778281490.HKD","LU0861579265.USD","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666371445","title":"諾華公司一款降膽固醇藥物在臨床試驗中失敗，Royalty Pharma股價下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2666371445","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666371445?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 00:41","pubTimestamp":1788885660,"startTime":"0","endTime":"0","summary":"——Royalty Pharma** RPRX重申“其2030年投资组合收入目标为47亿美元或更高”** 计入本交易日涨幅，该股今年以来累计上涨54.7%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4T4501DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IHE","TBXU","BBH","BK4588","LU2112291526.USD","BK4533","BK4566","AMGN","BK4585","IBBQ","BIB","RPRX","PBE","LU1571399168.USD","LU1983299246.USD","LU0289739699.SGD","BK4534","BK4139","IE00BJT1NW94.SGD","LU1061106388.HKD","LU2242646821.SGD","SG9999001440.SGD","LU0058720904.USD","LU1057294990.SGD","BK4007","LU0320765992.SGD","PJP","IE00BJJMRZ35.SGD","LU0122379950.USD","LU0868494617.USD","LU1023059063.AUD","LU0889565916.HKD","IE0009355771.USD","BK4581","IE0002141913.USD","LU0109394709.USD","IE00B4R5TH58.HKD","LU2089984988.USD","IE00B2B36J28.USD","LU2242652126.USD","IONS","IE00BFTCPJ56.SGD","BK4599","LU2468319806.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":6,"totalSize":214,"code":"91000000","status":"200"}]}}